Details for Patent: 7,713,930
✉ Email this page to a colleague
Title: | Acidic insulin preparations having improved stability |
Abstract: | The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range. |
Inventor(s): | Brunner-Schwarz; Anette (Frankfurt, DE), Lill; Norbert (Kronberg, DE) |
Assignee: | Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE) |
Filing Date: | Dec 04, 2008 |
Application Number: | 12/328,208 |
Claims: | 1. A pharmaceutical formulation comprising Gly(A21), Arg(B31), Arg(B32)-human insulin; at least one chemical entity chosen from esters and ethers of polyhydric alcohols; at least one preservative; and water, wherein the pharmaceutical formulation has a pH in the acidic range from 1 to 6.8. 2. The pharmaceutical formulation as claimed in claim 1, wherein the at least one preservative is chosen from phenols. 3. The pharmaceutical formulation as claimed in claim 1, wherein the at least one preservative is cresol. 4. The pharmaceutical formulation as claimed in claim 3, further including zinc. 5. The pharmaceutical formulation as claimed in claim 1, further including at least one isotonicizing agent. 6. The pharmaceutical formulation as claimed in claim 4, wherein the pharmaceutical formulation has a pH in the acidic range from 3.5 to 6.8. 7. The pharmaceutical formulation as claimed in claimed 6, wherein the pharmaceutical formulation has a pH in the acidic range from 3.5 to 4.5. 8. The pharmaceutical formulation as claimed in claim 1, wherein the at least one preservative is chosen from phenol, cresol, chlorocresol, benzyl alcohol, and parabens. 9. The pharmaceutical formulation as claimed in claim 5, wherein the at least one isotonicizing agent is chosen from mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, and glycerol. 10. The pharmaceutical formulation as claimed in claim 1, further comprising a buffer. 11. The pharmaceutical formulation as claimed in claim 10, wherein the buffer is chosen from TRIS, phosphate, citrate, acetate, and glycylglycine. 12. The pharmaceutical formulation as claimed in claim 1, wherein the Gly(A21), Arg(B31), Arg(B32)-human insulin is present in a concentration of 60-6000 nmol/ml. 13. The pharmaceutical formulation as claimed in claim 12, wherein the Gly(A21), Arg(B31), Arg(B32)-human insulin is present in a concentration of 240-3000 nmol/ml. 14. The pharmaceutical formulation as claimed in claim 1, wherein the at least one chemical entity is present in a concentration of 5-200 .mu.g/ml. 15. The pharmaceutical formulation as claimed in claim 14, wherein the at least one chemical entity is present in a concentration of 5-120 .mu.g/ml. 16. The pharmaceutical formulation as claimed in claim 15, wherein the at least one chemical entity is present in a concentration of 20-75 .mu.g/ml. 17. The pharmaceutical formulation as claimed in claim 9, wherein at least one isotonicizing agent is chosen from glycerol and mannitol and wherein said at least one isotonicizing agent is present in a concentration of 100-250 mM. 18. The pharmaceutical formulation as claimed in claim 1, further comprising one or more excipients chosen from acids, alkalis and salts. 19. The pharmaceutical formulation as claimed in claim 18, wherein the excipient is NaCl which is present in a concentration of up to 150 mM. 20. The pharmaceutical formulation as claimed in claim 10, wherein said buffer is present in a concentration of 5-250 mM. |